Real-time inventory software enables travelers to book a last minute flight and have their boarding passes in hand at security a few minutes later. But that technology isn't utilized in other aspects of a vacation — tour companies, for example. That's where San Francisco-based Xola comes in.

Scott Zimmerman and his co-founder Anush Ramani realized real-time technology was a glaring hole in a multi-billion-dollar business. It's why they founded Xola, a booking and marketing software system designed for tour and activity companies.

"So many smaller tour companies operate with pen and paper," Zimmerman explained. "And for many cities and countries, tourism is the number-two or number-three industry — it's a huge driver of economic growth. It's a $120 billion global market."

They created Xola as a B2B solution that created a platform for operators to promote their offerings, and allow customers to purchase tours and activities. Meanwhile, Xola's custom-design software platform managed the tour inventory and payments, providing real-time inventory management.

Since its inception in 2011, Xola has emerged as a leading B2B solution for travel industry operators. The company started in San Francisco, but opened an office in Houston in 2016 in the Heights Clock Tower. Xola's Houston operation began with six people; today, it employs 17. Zimmerman says he sees potential to grow the team with additional marketing, sales, and support staff.

"We serve customers around the world, and Houston has everything we need to continue our growth."

Zimmerman acknowledged the cost of doing business in the Bay Area is expensive, but when he went looking for cities in which to expand, price wasn't his only concern.

"We wanted a large metropolitan area, with a diverse ecosystem, good universities, a great talent pool, a high quality of life and an affordable cost of living. Houston has all these things. And the more I get to know the city, I realize just how much it has going on."

Zimmerman said that the city has "totally exceeded" his expectations in terms of Xola's growth. He said every one of the Houston employees is wonderful to work with, and loves that they come from diverse cultural and educational backgrounds.

"I can't quite describe what the office is like, but there's a great energy and enthusiasm. [The team] easy to work with. It's been fun in that regard."

Zimmerman said that Houston's talent pool is so extensive, he can't imagine "ever exhausting" the city's resources. He also sees Houston as an asset for Xola's continued growth. The company currently has offices in San Francisco, Houston, Bangalore, and Belgrade and anticipates more expansion in the coming years. Xola's ticketing and software system has received multiple five-star reviews from its customers, who praise not only its ease of operation, but also the company's stellar customer service. In fact, Xola just won a 2018 Ease of Use Award from Capterra.

"In addition to Xola's core booking system, we're building next-generation automated marketing features that help our customers maintain a competitive edge. And our Houston team will continue to grow as we do, so we can continue to serve markets around the world."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.